Bicycle Therapeutics (BCYC) Receivables - Net (2018 - 2025)

Bicycle Therapeutics' (BCYC) quarterly Receivables - Net came in at $136000.0 in Q1 2025, down 41.63% on a QoQ basis from $233000.0 in Q2 2024.

Bicycle Therapeutics (BCYC) Receivables - Net (2018 - 2025) Analysis & Trends

Bicycle Therapeutics (BCYC) has 8 years of Receivables - Net data on file, last reported at $136000.0 in Q1 2025.

Quarterly Receivables - Net changed N/A year-over-year to $136000.0 in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $136000.0 (changed N/A YoY) and the FY2022 annual result came in at $2.0 million, up 104.5% from the prior year.
Receivables - Net slipped to $136000.0 in Q1 2025, from $233000.0 in the prior quarter.
In the past five years, Receivables - Net ranged from a high of $50.0 million in Q1 2023 to a low of $136000.0 in Q1 2025.
A 5-year average of $13.8 million and a median of $2.0 million in 2021 frame the typical range for Receivables - Net.
Annual changes were most pronounced in 2023 — Receivables - Net soared 350.9% — and 2024, when it sank 99.48%.
Tracing BCYC's Receivables - Net over 5 years: stood at $1.0 million in 2021, then jumped by 104.5% to $2.0 million in 2022, then surged by 2104.89% to $45.1 million in 2023, then slumped by 99.48% to $233000.0 in 2024, then tumbled by 41.63% to $136000.0 in 2025.
The last three Receivables - Net figures came in at $136000.0 (Q1 2025), $233000.0 (Q2 2024), and $45.1 million (Q2 2023), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Bicycle Therapeutics	272.28 Mn	272.28 Mn	-

Download Data